InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,142.47
(
0.40%
)
Post# of 83
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

busker

Send PM Follow Ignore
Followers 0
Posts 29
Boards Moderated 0
Alias Born 09/27/2006

busker

Re: None

Wednesday, 09/19/2007 11:30:50 PM

Wednesday, September 19, 2007 11:30:50 PM

Post# of 83
Orphan Drug Designation for PI-88 granted in the EU

Brisbane, Australia. 20 September 2007:
Progen Pharmaceuticals Limited (ASX: PGL; NASDAQ: PGLA) today announced that the Commission of the European Communities has granted orphan product designation for PI-88 for the treatment of hepatocellular carcinoma, or primary liver cancer.

This follows the positive recommendation received in August, from the European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Orphan Medical Products for PI-88 in this indication.
------------------------------

Good price action and high Progen volume on ASX today - up ~5%

(surf check your Ly...-mail - can't PM you)


busker.the.dog@lycos.com

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up